I like Dr. L a lot but let's keep it real. There is a strong scientific rationale for studying HCQ in mild patients based on excellent in vitro efficacy against CV-19, safety, and cost. More doctors believe this than for any other drug including Remdesivir. Dr. Raoult didn't just pull the drug out of a hat to test it and many would take offense at criticizing his data while praising leronlimab's anecdotal data

That being said leronlimab is likely the far more effective drug especially for sicker patients, and if cost and supply is no issue, maybe all patients. The reason it is was delayed was due to the focus on anti virals and leronlimab's nontraditional mechanism of action. We all buy it's excellent immunomodulating effects but the mainstream scientific community has not YET, and has had to think outside the box to consider it as a viable therapeutic against CV-19. Just keeping it real.